# Bristol-Myers Squibb: Phase 3 study completed, 1314 enrolled (Urothelial Cancer)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer |
| NCT ID | NCT03036098 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Urothelial Cancer |
| Intervention types | biological, drug |
| Target enrollment | 1314 |
| Site countries | United States, Argentina, Australia, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany |
| Posted | 2017-01-30 |
| Planned start | 2017-03-24 |
| Event | Completed |
| Event date | 2026-10-20 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 1314 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03036098). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.